2,189 results match your criteria: "San Francisco Veterans Affairs Medical Center.[Affiliation]"

Gamma oscillations and excitation/inhibition imbalance: parallel effects of N-methyl D-aspartate receptor antagonism and psychosis.

Biol Psychiatry Cogn Neurosci Neuroimaging

January 2025

San Francisco Veterans Affairs Medical Center, San Francisco, CA, United States; University of California, San Francisco, San Francisco, CA, United States. Electronic address:

Background: Auditory steady-state response (ASSR) abnormalities in the 40-Hz (gamma band) frequency have been observed in schizophrenia and rodent studies of N-methyl D-aspartate glutamate receptor (NMDAR) hypofunction. However, the extent to which 40-Hz ASSR abnormalities in schizophrenia resemble deficits in 40-Hz ASSR induced by acute administration of ketamine, an NMDAR antagonist, is not yet known.

Methods: To address this knowledge gap, we conducted parallel EEG studies: a crossover, placebo-controlled ketamine drug challenge study in healthy subjects (Study 1) and a comparison of patients with schizophrenia and healthy controls subjects (Study 2).

View Article and Find Full Text PDF

A systematic review of participant diversity in psychedelic-assisted psychotherapy trials.

Psychiatry Res

January 2025

University of California San Francisco, Department of Psychiatry and Behavioral Sciences, 675 18th Ave. San Francisco, CA 94121, USA; San Francisco Veteran's Affairs Medical Center, 4150 Clement St. San Francisco, CA 94121, USA.

A lack of diverse and representative participant samples in mental health intervention research perpetuates mental health disparities. This issue has become a salient concern in studies of psychedelic-assisted psychotherapy (PAT), which is emerging as a promising mental health intervention. This systematic review evaluates the reporting, representation, and analysis of participant sociodemographic characteristics in randomized controlled trials (RCTs) of PAT.

View Article and Find Full Text PDF

Purpose: To report the experience with an alternative to the upper eyelid pentagonal wedge resection technique which results in improved cosmesis due to a greater alignment of incisions with relaxed skin tension lines.

Methods: A retrospective review of all patients who underwent the T-shaped wedge resection by the authors from 2009 to 2017. A horizontal eyelid crease incision is made across the upper eyelid skin.

View Article and Find Full Text PDF

Background: Effective pain recognition and treatment in perioperative environments reduce length of stay and decrease risk of delirium and chronic pain. We sought to develop and validate preliminary computer vision-based approaches for nociception detection in hospitalized patients.

Methods: Prospective observational cohort study using red-green-blue camera detection of perioperative patients.

View Article and Find Full Text PDF

Background: Interpersonal violence (IPV) affects half of women living with HIV (WLHIV) in the United States and has important consequences for mental health and HIV outcomes. Although different types of stigmas (eg, HIV- or sexual identity-related) are associated with increased risk of IPV, the relationship between poverty-related stigma and IPV is unclear, even though poverty frequently co-occurs with IPV.

Methods: Data from up to 4 annual visits (2016-2020) were collected from 374 WLHIV enrolled in a substudy of the Women's Interagency HIV Study (now known as Multicenter AIDS Cohort Study/Women's Interagency HIV Study Combined Cohort Study) at 4 sites across the United States.

View Article and Find Full Text PDF

Modifying Informed Consent to Help Address Functional Unmasking in Psychedelic Clinical Trials.

JAMA Psychiatry

January 2025

Department of Psychiatry and Behavioral Sciences, Weill Institute for Neurosciences, University of California, San Francisco.

Importance: There is unprecedented clinician, industry, and patient interest in the therapeutic development of psychedelic drugs. This is due to a combination of promising clinical trial results, positive media coverage, and the lack of novel pharmacologic treatments for psychiatric disorders in recent decades. However, the field faces a key methodological challenge: masking participants to treatment conditions in psychedelic clinical trials has been largely unsuccessful.

View Article and Find Full Text PDF

The Centers for Medicare and Medicaid Services (CMS) coverage with evidence development (CED) program provides coverage for items and services not meeting Medicare's "reasonable and necessary" standard while requiring participation in clinical studies. As additional evidence is available, CMS may reconsider CED decisions. Of twenty-six items and services in the CED program since its 2005 inception, CMS has reconsidered coverage for ten (38 percent).

View Article and Find Full Text PDF

Purpose: To employ a validated survey for evaluation of quality of life (QoL) outcomes and associated factors in a US cohort of adult patients with acquired anophthalmia wearing a prosthesis.

Methods: A retrospective cohort study was performed at a single, US academic institution of patients cared for between 2012 and 2021. The electronic medical record database was queried for adult patients with a history of evisceration or enucleation surgery and placement of an orbital implant.

View Article and Find Full Text PDF

Research and Implementation of Psychedelic-Assisted Therapy in the Veterans Health Administration.

Am J Psychiatry

January 2025

Directorate of Behavioral Health, Walter Reed National Military Medical Center, Bethesda, Md. (Wolfgang); Department of Psychiatry, Uniformed Services University, Bethesda, Md. (Wolfgang, Benedek); Department of Psychiatry, Yale University School of Medicine, New Haven, Conn. (Wolfgang, Wiechers); Department of Veterans Affairs, Office of Research and Development, Washington, D.C. (McClair, Smyth, Tenhula); Department of Veterans Affairs, Executive Division, National Center for PTSD, White River Junction, Vt. (Schnurr, Holtzheimer); Department of Psychiatry, Geisel School of Medicine at Dartmouth, Hanover, N.H. (Schnurr, Holtzheimer); Department of Psychiatry and Behavioral Sciences, University of California, San Francisco. (Woolley, Wiechers); San Francisco Veterans Affairs Medical Center, San Francisco. (Woolley); Department of Psychiatry, Oregon Health and Science University, Portland, Ore. (Stauffer); Department of Mental Health; VA Portland Health Care System, Portland, Ore. (Stauffer); Substance Abuse and Mental Health Services Administration, Rockville, Md. (Wolf); Department of Health and Human Services, Office of the Assistant Secretary for Health, Washington, D.C. (States); Department of Psychiatry, Harvard Medical School, Boston (Bradley); VA Boston Healthcare System, Boston (Bradley); Department of Veterans Affairs, Pharmacy Benefits Management Service, Washington, D.C. (Fuller); Department of Psychiatry, Case Western Reserve University, Cleveland, Ohio (Fuller); Department of Veterans Affairs, Northeast Program Evaluation Center, Office of Mental Health, Washington, D.C. (Hermes); Veterans Health Administration Office of Mental Health, Washington, D.C. (Wiechers).

View Article and Find Full Text PDF

Background: After a new drug or medical device is approved by the US Food and Drug Administration (FDA), physician-patient communication about benefits and risks is critical, including whether the product was approved through an expedited pathway based on limited evidence. In addition, physician reporting of drug- and device-related adverse events in real-world use is necessary to have a complete safety profile. We studied physician-reported communication and safety-reporting practices related to drugs and devices.

View Article and Find Full Text PDF

Aims: Serelaxin is recombinant human relaxin-2, a hormone responsible for haemodynamic adaptations and organ protection in pregnancy. In the RELAX-AHF trial, serelaxin demonstrated reductions in cardiac, renal and hepatic damage. In RELAX-AHF-2, organ damage-related biomarkers were assessed in a biomarker substudy.

View Article and Find Full Text PDF

Schizophrenia is a chronic brain disorder associated with widespread alterations in functional brain connectivity. Although data-driven approaches such as independent component analysis are often used to study how schizophrenia impacts linearly connected networks, alterations within the underlying nonlinear functional connectivity structure remain largely unknown. Here we report the analysis of networks from explicitly nonlinear functional magnetic resonance imaging connectivity in a case-control dataset.

View Article and Find Full Text PDF

New and future heart failure drugs.

Nat Cardiovasc Res

December 2024

Section of Cardiology, San Francisco Veterans Affairs Medical Center and School of Medicine, University of California, San Francisco, San Francisco, CA, USA.

In the past decade, our understanding of heart failure pathophysiology has advanced significantly, resulting in the development of new medications such as angiotensin-neprilysin inhibitors, sodium-glucose cotransporter-2 inhibitors and oral soluble guanylate cyclase stimulators. Backed by positive findings from large randomized controlled trials, recommendations for their use were recently included in the 2022 AHA/ACC/HFSA guidelines and 2023 ESC guidelines for management of heart failure. Promising drugs for future heart failure treatment include agents that modulate the neurohormonal system, vasodilators, anti-inflammatory drugs, mitotropes, which improve deranged energy metabolism of the failing heart, and myotropes, which increase cardiac contractility by affecting cardiac sarcomere function.

View Article and Find Full Text PDF

Under the 21st Century Cures Act of 2016, a summary of the evidence used to support local coverage determinations, which represent the vast majority of Medicare's coverage decisions for new technologies, must be made publicly accessible. Using reports from the Medicare Coverage Database on local coverage determinations and the medical literature, we examined the availability of these decisions and the quality of evidence cited for therapeutic drugs, biologics, and moderate- or high-risk devices during the period 2015-22 to understand whether evidence strength and generalizability differed for indications with favorable versus unfavorable coverage decisions. Evidence summaries were publicly available for 26 percent of coverage decisions originally effected during 2015-18 and 100 percent during 2019-22.

View Article and Find Full Text PDF

Objective: To analyze the variability in new infliximab biosimilar starts as well as switching from bio-originator to biosimilar infliximab, across insurance payers and rheumatology practices nationally.

Study Setting And Design: Data came from Rheumatology Informatics System for Effectiveness, a national registry with electronic health records from over 1100 US rheumatologists. Key outcomes include ever use of a biosimilar, date of initiation, and date of switching.

View Article and Find Full Text PDF

Decongestion and Outcomes in Patients Hospitalized for Acute Heart Failure: Insights From the RELAX-AHF-2 Trial.

JACC Heart Fail

November 2024

Institute of Cardiology, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy. Electronic address:

Background: The prognostic importance of residual congestion after acute heart failure (AHF) hospitalization is still debated.

Objectives: The authors aimed to assess the impact of residual congestion in a large cohort of patients with AHF enrolled in the RELAX-AHF-2 (Relaxin in Acute Heart Failure 2) trial.

Methods: Residual congestion was assessed at day 5 after admission among hospitalized patients using an established composite congestion score (CCS) based on the presence of orthopnea, peripheral edema, and increased jugular venous pressure, ranging from 0 to 8 points.

View Article and Find Full Text PDF
Article Synopsis
  • There's a growing population of older adults with kidney disease, but there's not enough evidence to help improve their clinical care, prompting the KDARC to conduct a study on research priorities in geriatric nephrology.
  • The study used a modified Delphi approach involving clinicians and researchers in the US and Canada to gather and prioritize important research topics for better care of older adults with kidney issues.
  • Five key research priorities were identified: improving communication about treatment options, enhancing quality of life and symptom management, addressing frailty, tailoring therapies for older adults, and providing caregiver support, all underlined by the importance of health equity and patient-centered care.
View Article and Find Full Text PDF

Frailty is a syndrome that can inform clinical treatments and interventions for older adults. Although implementation of frailty across medical subspecialties has the potential to improve care for the aging population, its uptake has been heterogenous. While frailty assessment is highly integrated into certain medical subspecialties, other subspecialties have only recently begun to consider frailty in the context of patient care.

View Article and Find Full Text PDF

Maternal care is associated with neural and behavioral effects of oxytocin administration during empathic accuracy in schizophrenia and controls.

Psychoneuroendocrinology

November 2024

University of California, San Francisco, Department of Psychiatry, USA; San Francisco Veterans Affairs Medical Center, USA; UCSF Weill Institute for Neurosciences, USA. Electronic address:

Article Synopsis
  • * The study examined whether oxytocin, delivered intranasally, could enhance empathic accuracy in those with schizophrenia compared to a placebo, while considering the influence of early maternal care.
  • * Results showed no overall improvement in empathic accuracy from oxytocin for either group; however, those with better maternal care had the most notable improvements, suggesting early social experiences can affect responses to oxytocin treatment.
View Article and Find Full Text PDF

Optimizing the Posthospital Period After Admission for Worsening Heart Failure.

JACC Heart Fail

January 2025

Section of Cardiology, San Francisco Veterans Affairs Medical Center, San Francisco, CA, USA; School of Medicine, University of California-San Francisco, San Francisco, CA, USA.

View Article and Find Full Text PDF

Information Disclosure, Medical Device Regulation, and Device Safety: The Case of Cook Celect IVC Filters.

Ann Intern Med

December 2024

Center for Outcomes Research and Evaluation, Yale New Haven Hospital; Department of Health Policy and Management, Yale School of Public Health; and Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut (H.M.K.).

Article Synopsis
  • * Evidence from court documents shows that the Celect IVC filter’s clinical study did not adhere to FDA guidelines and had inadequate methods for detecting serious complications.
  • * The misreporting of adverse events and patient deaths raises concerns about the accuracy of safety information provided to both clinicians and patients, underlining a need for reform in medical device regulations.
View Article and Find Full Text PDF

Bladder exstrophy in adulthood: A narrative review of transitional health.

J Pediatr Urol

November 2024

Department of Urology, School of Medicine, University of California San Francisco, 400 Parnassus Ave, San Francisco, CA, 94143, USA; Department of Surgery, San Francisco Veterans Affairs Medical Center, 4150 Clement St, San Francisco, CA, 94121, USA.

Background: Exstrophy-epispadias complex (EEC) classically presents as bladder exstrophy (BE) and requires lifetime urologic care. As men and women with BE age, there is an often difficult period of transition to adulthood in terms of addressing urologic and general health challenges. BE can lead to many urinary and sexual health issues as these patients age, which is often made more complex given their past surgical history and anatomy.

View Article and Find Full Text PDF